Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Marianna Fontana(Johnson & Johnson (United States)), Mathew S. Maurer(Boston University), Ronald Witteles(British Heart Foundation), John L. Berk(Université Paris-Sud), Kenichi Tsujita(British Heart Foundation), José González‐Costello(British Heart Foundation), Steen Hvitfeldt Poulsen(Amyloidosis Foundation), Diego Delgado(British Heart Foundation), Antoine Bondue, Elena Yureneva(British Heart Foundation), Zoltán Pozsonyi(British Heart Foundation), Farooq H. Sheikh(British Heart Foundation), Scott D. Solomon(Brigham and Women's Hospital), Katherine L. Boyle(British Heart Foundation), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ali Abbas Yılmaz(British Heart Foundation), Pablo García‐Pavía(Universidad Francisco de Vitoria), Vincent Algalarrondo(British Heart Foundation), Darae Kim(British Heart Foundation), Nancy Silliman(British Heart Foundation), Brian Drachman(British Heart Foundation), Thibaud Damy(Amyloidosis Foundation), Pushkal Garg(Université Paris-Sud), Martha Grogan(Boston University), Ewa A. Jankowska, Nobuhiro Tahara(British Heart Foundation), Jörg Täubel(British Heart Foundation), Caroline Morbach(British Heart Foundation), Andrew Slugg(British Heart Foundation), Jihong Chen(Université Paris-Sud), Peter van der Meer(University Medical Center Groningen), Satish A. Eraly(British Heart Foundation), Lilli Yang(British Heart Foundation), Olga Azevedo(British Heart Foundation), Andrew Jabbour(British Heart Foundation), Mark C. Petrie(Copenhagen University Hospital)
Cited by 356
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k